Kelun-Biotech and Crescent Biopharma Partner to Develop Oncology Therapeutics
ByAinvest
Thursday, Dec 4, 2025 7:54 am ET1min read
CBIO--
Kelun-Biotech and Crescent Biopharma have formed a strategic partnership to develop and commercialize novel oncology therapeutics. The companies will advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate, in global markets and China. The collaboration aims to accelerate and expand the development of synergistic combinations with CR-001 and ADCs. CR-001 and SKB105 are on track to enter Phase 1/2 monotherapy clinical trials in Q1 2026, followed by combination studies.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet